Premium
Selenium, but not lycopene or vitamin E, decreases growth of transplantable Dunning R3327‐H prostate tumors.
Author(s) -
Lindshield Brian L,
Ford Nikki A,
CaneneAdams Kirstie,
Wallig Matthew A,
Erdman John W
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a58-d
Subject(s) - selenium , lycopene , micronutrient , prostate cancer , vitamin e , endocrinology , medicine , androgen , chemistry , vitamin , tocopherol , prostate , antioxidant , cancer , biology , biochemistry , hormone , organic chemistry
Lycopene, selenium, and vitamin E are three commonly consumed and supplemented micronutrients that have been associated with decreased risk of prostate cancer. However, there is little data on the effectiveness of these compounds in vivo . Therefore, we evaluated the effects of lycopene (250 mg/kg diet), selenium (Se‐methylselenocysteine, 2 mg/kg diet), and vitamin E (γ‐tocopherol, 200 mg/kg diet) alone and in combination on the growth of androgen‐dependent Dunning R3327‐H tumors. AIN‐93G based diets were prefed for 4–7 weeks prior to tumor implantation by subcutaneous injection, which were allowed to grow for ~18 weeks. Multiple linear regression analysis found that selenium consumption resulted in a highly significant decrease in tumor weight (p = 0.003) and areas (p = 0.003). Lycopene intake resulted in a minor, nonsignificant reduction in tumor weights and areas, while γ‐tocopherol consumption led to a nonsignificant increase in tumor weights and areas. There were no significant interactions among nutrient combinations. The decrease in tumor growth was not a result in lower serum androgen levels, because there were no differences in serum testosterone or dihydrotestosterone among the different dietary groups. In conclusion, among the three micronutrients studied, only Se‐methylselenocysteine consumption reduced growth of transplantable Dunning R3327‐H prostate tumors (AICR Grant 05A021).